Funding Round
Neuraly raises $76M Series B for gut-brain axis drug targeting depression and Parkinson's
Endpoints News4/2/2026·04/02/26🌐 USA
Summary
Neuraly closed a $76M Series B from Pfizer Ventures, AbbVie Ventures, Eli Lilly, and Biogen Ventures — an unusually broad pharma investor syndicate. Lead compound NAL-101 targeting enteric serotonin receptors enters Phase 2 for depression. Pharma investors gain option rights to co-develop compounds in their respective therapeutic areas.
Why it matters
Four pharma companies co-investing with option rights is a strong validation signal. The gut-brain axis is one of psychiatry's most promising new target spaces, and Neuraly's ability to attract Lilly, AbbVie, Pfizer, and Biogen simultaneously suggests the mechanism is highly credible.
#Depression#Industry#Neuropharmacology#Parkinson's#USA#Venture Capital
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in